Related Experiment Videos
[New indications for gamma globulins]
G Fontán1, M C García, D Pascual-Salcedo
1Unidad de Inmunología, Hospital La Paz, Madrid, España.
Anales Espanoles De Pediatria
|June 1, 1992
Summary
Intravenous immunoglobulin (IV Ig) effectively treats primary immunodeficiencies and has proven uses in secondary immunodeficiencies and certain immune disorders. Further trials are needed to confirm its efficacy in other potential applications.
Area of Science:
- Immunology
- Pharmacology
Context:
- Intravenous immunoglobulin (IV Ig) is established for primary immunodeficiencies impacting IgG antibody production.
- Its application has expanded to secondary immunodeficiencies like chronic lymphocytic leukemia and HIV infection.
- IV Ig is also beneficial in cytomegalovirus infections among transplant recipients.
Purpose:
- To review the established and potential therapeutic indications of IV Ig.
- To highlight the need for further research into IV Ig's mechanism of action in immunoregulatory disorders.
Summary:
- IV Ig demonstrates therapeutic value in primary immunodeficiencies and has proven utility in secondary immunodeficiencies and specific immune and inflammatory conditions such as immune thrombocytopenic purpura and Kawasaki syndrome.
- Preliminary evidence suggests potential benefits in neurological and autoimmune conditions including myasthenia gravis, Guillain-Barré syndrome, and polymyositis.
- The precise mechanisms underlying IV Ig's efficacy in these immunoregulatory disorders remain largely unknown.
Impact:
- IV Ig has several confirmed therapeutic uses and numerous potential applications.
- Controlled clinical trials are essential to validate the effectiveness of IV Ig in a broader range of conditions.
- This review underscores the evolving role of IV Ig in clinical practice and the necessity for rigorous scientific investigation.